Abstract
Immediate type hypersensitivity reactions due to heparins are rare, and the exact immunologic pathomechanism has not been identified so far. In our 2 case reports, we describe first a 50-year-old female who received dalteparin (Fragmin®) and developed signs of an immediate type hypersensitivity reaction. The personal history revealed a previous application of dalteparin (Fragmin®). Evaluation with a skin prick test showed positive results for dalteparin. The second case deals with a 73-year-old female with a suspected immediate type reaction after the administration of dalteparin (Fragmin®). A skin prick test was negative but intracutaneous tests showed a positive reaction to the causative agent. Both cases indicated cross-reactivity reactions for low-molecular-weight heparin (LMWH) but not for unfractioned heparin (UFH) or fondaparinux. In conclusion, our case reports including a review of published cases of immediate type hypersensitivity reactions after the application of heparins illustrate this rare complication. Mostly, the causative agent can be identified with a skin test, which is highly suggestive of an IgE-mediated reaction. Therapeutic alternatives for patients with sensitization to an LMWH are UFH and fondaparinux. Both agents have a small risk of cross-reactivity compared to heparins of the same substance class.
Journal Section:
Editor's choice
References
1.
Gray E, Mulloy B, Barrowcliffe TW: Heparin and low-molecular-weight heparin. Thromb Haemost 2008;99:807-818.
[PubMed]
2.
Arepally GM, Ortel TL: Clinical practice: heparin-induced thrombocytopenia. N Engl J Med 2006;355:809-817.
[PubMed]
3.
Bircher AJ, Harr T, Hohenstein L, Tsakiris DA: Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy 2006;61:1432-1440.
[PubMed]
4.
Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, et al: Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008;358:2457-2467.
[PubMed]
5.
Schindewolf M, Lindhoff-Last E, Ludwig RJ, Boehncke WH: Heparin-induced skin lesions. Lancet 2012;380:1867-1879.
[PubMed]
6.
Bottio T, Pittarello G, Bonato R, Fagiolo U, Gerosa G: Life-threatening anaphylactic shock caused by porcine heparin intravenous infusion during mitral valve repair. J Thorac Cardiovasc Surg 2003;126:1194-1195.
[PubMed]
7.
Tiu A, Pang JM, Martin R, Officer N: Allergic reactions to enoxaparin and heparin: a case report and review of the literature. N Z Med J 2004;117:U1126.
[PubMed]
8.
Basic-Jukic N, Kes P: Severe anaphylactic reaction in a haemodialysis patient after administration of reviparin. Nephrol Dial Transplant 2004;19:1021-1022.
[PubMed]
9.
Parissis H: Lepirudin as an alternative to “heparin allergy” during cardiopulmonary bypass. J Cardiothorac Surg 2011;6:44.
[PubMed]
10.
Berkun Y, Haviv YS, Schwartz LB, Shalit M: Heparin-induced recurrent anaphylaxis. Clin Exp Allergy 2004;34:1916-1918.
[PubMed]
11.
Ueda A, Nagase S, Morito N, Yotsumoto M, Ohba S, Hasegawa Y, Narita M, Koyama A: Anaphylactoid reaction induced by low-molecular-weight heparin in a hemodialysis patient. Nephron 2001;87:93-94.
[PubMed]
12.
Caballero MR, Fernandez-Benitez M: Allergy to heparin: a new in vitro diagnostic technique. Allergol Immunopathol (Madr) 2003;31:324-328.
[PubMed]
13.
Bekkenk MW, van Zuuren EJ: Immediate type hypersensitivity after injection of nadroparin (Fraxiparin). Thromb Haemost 2005;94:673-674.
[PubMed]
14.
Harr T, Scherer K, Tsakiris DA, Bircher AJ: Immediate type hypersensitivity to low molecular weight heparins and tolerance of unfractioned heparin and fondaparinux. Allergy 2006;61:787-788.
[PubMed]
15.
Kavut AB, Koca E: Successful desensitization with un-fractionated heparin in a patient with heparin allergy and tolerance to fondaparinux. Asian Pac J Allergy Immunol 2012;30:162-166.
[PubMed]
16.
Anders D, Trautmann A: Allergic anaphylaxis due to subcutaneously injected heparin. Allergy Asthma Clin Immunol 2013;9:1.
[PubMed]
17.
Gelardi M, Ciprandi G, Buttafava S, Quaranta N, Squeo V, Incorvaia C, Frati F: Nasal inflammation in Parietaria-allergic patients is associated with pollen exposure. J Investig Allergol Clin Immunol 2014;24:352-353.
[PubMed]
18.
Balthazar S, Watremez C, Vigneault L, Eeckhoudt S, Pirson F, Hermans C: Management of anticoagulation during cardiopulmonary bypass in a patient with allergy to heparin and heparin-like compounds: a case-report. Blood Coagul Fibrinolysis 2014;25:900-903.
[PubMed]
19.
Pfohler C, Muller CS, Pindur G, Eichler H, Schafers HJ, Grundmann U, Tilgen W: Delayed-type heparin allergy: diagnostic procedures and treatment alternatives - a case series including 15 patients. World Allergy Organ J 2008;1:194-199.
[PubMed]
20.
Gonzalez P, de la Sen ML, Venegas I, Ramon A, Soriano V, Cueva B, Fernandez J: Immediate hypersensitivity to heparins: a cross-reactivity study. J Investig Allergol Clin Immunol 2014;24:367-368.
[PubMed]
21.
Weberschock T, Meister AC, Bohrt K, Schmitt J, Boehncke WH, Ludwig RJ: The risk for cross-reactions after a cutaneous delayed-type hypersensitivity reaction to heparin preparations is independent of their molecular weight: a systematic review. Contact Dermatitis 2011;65:187-194.
[PubMed]
22.
Maetzke J, Hinrichs R, Staib G, Scharffetter-Kochanek K: Fondaparinux as a novel therapeutic alternative in a patient with heparin allergy. Allergy 2004;59:237-238.
[PubMed]
23.
Petitou M, Herault JP, Bernat A, Driguez PA, Duchaussoy P, Lormeau JC, Herbert JM: Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 1999;398:417-422.
[PubMed]
24.
Gaigl Z, Pfeuffer P, Raith P, Brocker EB, Trautmann A: Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study. Br J Haematol 2005;128:389-392.
[PubMed]
25.
Jappe U: Allergy to heparins and anticoagulants with a similar pharmacological profile: an update. Blood Coagul Fibrinolysis 2006;17:605-613.
[PubMed]
26.
Scherer Hofmeier K, Bircher AJ: Hypersensitivity reactions to modern antiplatelet and anticoagulant drugs. Allergo J Int 2015;24:58-66.
[PubMed]
© 2017 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.
